Review



cd90 microbeads  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Miltenyi Biotec cd90 microbeads
    Cd90 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 120 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90+MicroBeads%2C+human/pm41986718-591-0-2
    Average 94 stars, based on 120 article reviews
    cd90 microbeads - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Cell-type-targeted mitochondrial transplantation rescues cell degeneration.
    Article Snippet: T em urkhan Ayupov, Verónica Moreno-Juan, Serena Curtoni, Alex Fratzl, Upnishad Sharma, Susana Posada-Céspedes, Ramona Ratiu, Rei Morikawa, Alexandra Graff Meyer, Margherita Pezzoli, Glenn Bantug, Morgan Chevalier, Yanyan Hou, Sarah A. Nadeau, Álvaro Herrero-Navarro, Vikram Ayinampudi, Elizabeth Kastanaki, Natasha Whitehead, Rebecca A. Siwicki, Mariana M. Ribeiro, Ji Hoon Han, Annalisa Bucci, Christoph Hess, Simone Picelli, Magdalena Renner, Daniel J. Müller, Cameron S. Cowan, Simon Hansen & Botond Roska1,2 ✉

    Article Title: A Metastasis-Competent CAF Subpopulation Defined by MFAP5⁷THY1⁷ Co-expression Drives Prostate Cancer Metastasis via EMT Activation.
    Article Snippet: Background: The tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), contributes to prostate cancer (PCa) metastasis, however, the role of CAF heterogeneity remains incompletely characterized.. The study aims to identify and functionally characterize a metastasis-competent CAF subpopulation in PCa and evaluate its potential as a biomarker for predicting metastatic progression.. Methods: We integrated single-cell RNA sequencing data from 1,214 CAFs across 14 PCa specimens.

    Article Title: Cell-type-targeted mitochondrial transplantation rescues cell degeneration
    Article Snippet: The cell pellet was resuspended in MACS buffer (80 μl for 10 7 cells) containing autoMACS Rinsing solution (Miltenyi Biotec, 130-091-222) and 0.5% BSA solution (Miltenyi Biotec, 130-091-376). .. CD90 microbeads (Miltenyi Biotec, 130-096-253) were added to the cells (20 μl for 10 7 cells) and incubated for 15 min on ice. .. CD90 + cells were sorted on a MidiMACS magnetic separator in an LS column (Miltenyi Biotec, 130-042-302, 130-042-401).

    Magnetic Cell Separation:

    Article Title: A Metastasis-Competent CAF Subpopulation Defined by MFAP5⁷THY1⁷ Co-expression Drives Prostate Cancer Metastasis via EMT Activation.
    Article Snippet: Background: The tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), contributes to prostate cancer (PCa) metastasis, however, the role of CAF heterogeneity remains incompletely characterized.. The study aims to identify and functionally characterize a metastasis-competent CAF subpopulation in PCa and evaluate its potential as a biomarker for predicting metastatic progression.. Methods: We integrated single-cell RNA sequencing data from 1,214 CAFs across 14 PCa specimens.

    Article Title: Spatial and single-cell multi-omics reveal pro-angiogenic THY1⁺ fibroblast subtypes predicting prognosis in prostate cancer.
    Article Snippet: .. MACS enrichment: Initial enrichment was performed using human THY1 MicroBeads (Miltenyi Biotec, Cat. No. 130–096–253) with LS columns. .. Briefly, 5 × 107 cells were incubated with MicroBeads in MACS buffer for 20 min at 4 ◦C and then applied to a pre-wetted LS column positioned within a magnetic field.

    Article Title: Spatial and single-cell multi-omics reveal pro-angiogenic THY1 ⁺ fibroblast subtypes predicting prognosis in prostate cancer
    Article Snippet: .. MACS enrichment: Initial enrichment was performed using human THY1 MicroBeads (Miltenyi Biotec, Cat. No. 130–096–253) with LS columns. .. Briefly, 5 × 107 cells were incubated with MicroBeads in MACS buffer for 20 min at 4 °C and then applied to a pre-wetted LS column positioned within a magnetic field.

    Single Cell:

    Article Title: SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway.
    Article Snippet: .. CD44 and CD90 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were used to isolate CD44+ and CD90+ cells, respectively, from single cell suspensions of HCC cells. ..



    Similar Products

    94
    MedChemExpress t25 flasks
    T25 Flasks, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90%2FThy-1+Antibody/pm42833217-344-27-23
    Average 94 stars, based on 1 article reviews
    t25 flasks - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec cd90 antibody, anti-human
    Cd90 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90+Antibody%2C+anti-human/custom%40130-117-796%4042727576
    Average 95 stars, based on 1 article reviews
    cd90 antibody, anti-human - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology cd90
    Cd90, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/PE+Anti-Mouse+CD90+Antibody/pm42881448-350-68-85
    Average 94 stars, based on 1 article reviews
    cd90 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Proteintech anti cd90 antibody
    Isolation and phenotypic characterization of primary cells from different regions of the velvet antler. (A) Representative photographs illustrate tissue sampling from Formosan sika deer during the velvet stage. Samples were collected from three anatomically defined regions tip, shaft, and burr as indicated in the schematic diagram. (B) Histological analyses using Masson’s trichrome and hematoxylin and eosin (H&E) staining reveal pronounced regional differences in tissue architecture. The tip region is characterized by loose connective tissue enriched with a dense microvascular network, accompanied by numerous hair follicles and sebaceous glands, consistent with an actively proliferative and angiogenic microenvironment. The shaft region exhibits increased tissue compactness with partially organized collagen fibers and reduced vascular density, indicating progressive differentiation and matrix remodeling. In contrast, the burr region displays tightly packed collagen bundles and early ossification fronts, reflecting a transition toward tissue maturation and mineralization. Scale bars: 200 μm. (C) Schematic workflow showing the process of primary cell isolation from freshly harvested antler tissues. After surface sterilization, tissues from the tip, shaft, and burr were minced and enzymatically digested (collagenase I + dispase II), followed by filtration, centrifugation, and primary culture. (D) Representative phase-contrast images of primary cells derived from each region. Tip-derived cells exhibit spindle-shaped, fibroblast-like morphology; shaft-derived cells show mixed elongated and polygonal forms; and burr-derived cells appear broad and flattened with partial mineralization features. (E) Immunofluorescence staining of cells for α-SMA, CD31, CD44, VEGFA, VEGFR, <t>CD90,</t> OCT4, and Slug, with DAPI nuclear counterstaining. Tip-derived cells express stemness-associated markers (CD44, CD90, OCT4, Slug); shaft-derived cells are enriched in endothelial and angiogenic markers (VEGFA, VEGFR, CD31); and burr-derived cells display fibroblastic and pre-osteogenic characteristics (α-SMA, VEGF/VEGFR). Scale bars = 100 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; α-SMA, alpha-smooth muscle actin; CD31, cluster of differentiation 31; CD44, cluster of differentiation 44; CD90, cluster of differentiation 90; OCT4, octamer-binding transcription factor 4; Slug, snail family transcriptional repressor 2 (SNAI2); VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.
    Anti Cd90 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90+Antibody/pmc13689626-82-7-32
    Average 95 stars, based on 1 article reviews
    anti cd90 antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc cd90 cst 13801s rabbit 1 1000
    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for <t>CD90,</t> PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.
    Cd90 Cst 13801s Rabbit 1 1000, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/Thy1%2FCD90+Rabbit+mAb/pmc13626482-145-41-42
    Average 95 stars, based on 1 article reviews
    cd90 cst 13801s rabbit 1 1000 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    R&D Systems cd90
    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for <t>CD90,</t> PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.
    Cd90, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/Human+Mesenchymal+Stem+Cell+Marker+Antibody+Panel/pm42785307-212-28-33
    Average 93 stars, based on 1 article reviews
    cd90 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    Proteintech cd90
    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for <t>CD90,</t> PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.
    Cd90, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90+Antibody/pm42772408-121-23-25
    Average 95 stars, based on 1 article reviews
    cd90 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec cd90 pe
    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for <t>CD90,</t> PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.
    Cd90 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/CD90+Antibody%2C+anti-human%2C+REAfinity/10__36922_slash_or026140021-66-24-26
    Average 95 stars, based on 1 article reviews
    cd90 pe - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Bioss rabbit anti cd90
    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for <t>CD90,</t> PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.
    Rabbit Anti Cd90, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd90/Thy-1+Polyclonal+Antibody/10__4252_slash_wjsc__123933-66-23-25
    Average 94 stars, based on 1 article reviews
    rabbit anti cd90 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Isolation and phenotypic characterization of primary cells from different regions of the velvet antler. (A) Representative photographs illustrate tissue sampling from Formosan sika deer during the velvet stage. Samples were collected from three anatomically defined regions tip, shaft, and burr as indicated in the schematic diagram. (B) Histological analyses using Masson’s trichrome and hematoxylin and eosin (H&E) staining reveal pronounced regional differences in tissue architecture. The tip region is characterized by loose connective tissue enriched with a dense microvascular network, accompanied by numerous hair follicles and sebaceous glands, consistent with an actively proliferative and angiogenic microenvironment. The shaft region exhibits increased tissue compactness with partially organized collagen fibers and reduced vascular density, indicating progressive differentiation and matrix remodeling. In contrast, the burr region displays tightly packed collagen bundles and early ossification fronts, reflecting a transition toward tissue maturation and mineralization. Scale bars: 200 μm. (C) Schematic workflow showing the process of primary cell isolation from freshly harvested antler tissues. After surface sterilization, tissues from the tip, shaft, and burr were minced and enzymatically digested (collagenase I + dispase II), followed by filtration, centrifugation, and primary culture. (D) Representative phase-contrast images of primary cells derived from each region. Tip-derived cells exhibit spindle-shaped, fibroblast-like morphology; shaft-derived cells show mixed elongated and polygonal forms; and burr-derived cells appear broad and flattened with partial mineralization features. (E) Immunofluorescence staining of cells for α-SMA, CD31, CD44, VEGFA, VEGFR, CD90, OCT4, and Slug, with DAPI nuclear counterstaining. Tip-derived cells express stemness-associated markers (CD44, CD90, OCT4, Slug); shaft-derived cells are enriched in endothelial and angiogenic markers (VEGFA, VEGFR, CD31); and burr-derived cells display fibroblastic and pre-osteogenic characteristics (α-SMA, VEGF/VEGFR). Scale bars = 100 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; α-SMA, alpha-smooth muscle actin; CD31, cluster of differentiation 31; CD44, cluster of differentiation 44; CD90, cluster of differentiation 90; OCT4, octamer-binding transcription factor 4; Slug, snail family transcriptional repressor 2 (SNAI2); VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.

    Journal: Journal of Dental Sciences

    Article Title: Deer antler tip cell culture supernatant restores endothelial barrier function and angiotensin converting enzyme 2/endothelial nitric oxide synthase nitric oxide signaling impaired by Porphyromonas gingivalis lipopolysaccharide

    doi: 10.1016/j.jds.2025.07.3521

    Figure Lengend Snippet: Isolation and phenotypic characterization of primary cells from different regions of the velvet antler. (A) Representative photographs illustrate tissue sampling from Formosan sika deer during the velvet stage. Samples were collected from three anatomically defined regions tip, shaft, and burr as indicated in the schematic diagram. (B) Histological analyses using Masson’s trichrome and hematoxylin and eosin (H&E) staining reveal pronounced regional differences in tissue architecture. The tip region is characterized by loose connective tissue enriched with a dense microvascular network, accompanied by numerous hair follicles and sebaceous glands, consistent with an actively proliferative and angiogenic microenvironment. The shaft region exhibits increased tissue compactness with partially organized collagen fibers and reduced vascular density, indicating progressive differentiation and matrix remodeling. In contrast, the burr region displays tightly packed collagen bundles and early ossification fronts, reflecting a transition toward tissue maturation and mineralization. Scale bars: 200 μm. (C) Schematic workflow showing the process of primary cell isolation from freshly harvested antler tissues. After surface sterilization, tissues from the tip, shaft, and burr were minced and enzymatically digested (collagenase I + dispase II), followed by filtration, centrifugation, and primary culture. (D) Representative phase-contrast images of primary cells derived from each region. Tip-derived cells exhibit spindle-shaped, fibroblast-like morphology; shaft-derived cells show mixed elongated and polygonal forms; and burr-derived cells appear broad and flattened with partial mineralization features. (E) Immunofluorescence staining of cells for α-SMA, CD31, CD44, VEGFA, VEGFR, CD90, OCT4, and Slug, with DAPI nuclear counterstaining. Tip-derived cells express stemness-associated markers (CD44, CD90, OCT4, Slug); shaft-derived cells are enriched in endothelial and angiogenic markers (VEGFA, VEGFR, CD31); and burr-derived cells display fibroblastic and pre-osteogenic characteristics (α-SMA, VEGF/VEGFR). Scale bars = 100 μm. Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; α-SMA, alpha-smooth muscle actin; CD31, cluster of differentiation 31; CD44, cluster of differentiation 44; CD90, cluster of differentiation 90; OCT4, octamer-binding transcription factor 4; Slug, snail family transcriptional repressor 2 (SNAI2); VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor.

    Article Snippet: The antibodies used included anti-CD44 antibody (15675-1-AP), anti-CD90 antibody (27178-1-AP), anti-OCT4/POU5F1 antibody (60242-1-Ig), anti-SNAI2/SLUG antibody (12129-1-AP), anti-VEGFA antibody (19003-1-AP), anti-VEGFR2/KDR antibody (26415-1-AP), anti-CD31 antibody (11265-1-AP), and anti-α-SMA antibody (67735-1-Ig), all purchased from Proteintech Group, Inc. (Rosemont, IL, USA).

    Techniques: Isolation, Tissue, Sampling, Staining, Cell Isolation, Filtration, Centrifugation, Phase Contrast, Derivative Assay, Morphology, Immunofluorescence, Binding Assay, H&E Stain

    Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for CD90, PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: Ultracentrifugation‐based exploratory pre‐screening reveals heterogeneous stromal and myeloid surface‐marker patterns across synovial fluid EV isolates from arthritis patients. (a) Schematic overview of synovial tissue and major cell populations present in active arthritis. (b) Workflow for ultracentrifugation (UC)‐based exploratory pre‐screening of synovial fluid (SF)‐EV marker profiles. (c) Western blot analysis of UC‐derived bulk SF‐EV preparations from patients with different forms of arthritis (total n = 13; RA n = 6, CPPD n = 4, Gout n = 1, OA n = 2) loaded by equal total protein amounts (50 µg per lane) and probed for CD90, PDPN, CD68, CD48, CD163, syntenin‐1 and human serum albumin. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts (FLS) and M1‐like macrophages (M1) were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, the marker panels shown were derived from the same immunoblot. (d) Relative distribution of selected markers across donor‐derived SF‐EV preparations. Densitometric quantification of marker signals normalised to the corresponding syntenin‐1 signal, shown as the percentage contribution of normalised intensity across donor samples. CPPD, calcium pyrophosphate deposition (CPPD) arthritis; OA, osteoarthritis; RA, rheumatoid arthritis.

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: Screening, Marker, Tissue, Western Blot, Analysis, Derivative Assay, Cell Culture

    In Vitro validation of CD90‐ and PDPN‐directed immunocapture of synovial fibroblast‐derived EVs following SEC‐UF enrichment. (a) Schematic of the size exclusion chromatography‐ultrafiltration (SEC‐UF) workflow used to enrich EVs from conditioned medium (CM) of cultured synovial fibroblasts. (b) Representative transmission electron microscopy (TEM) images of SEC‐UF‐enriched EVs from two arthritis‐derived synovial fibroblasts (RA and OA donor). (c) Nano‐flow cytometry (nFCM) single‐vesicle surface staining of synovial fibroblast‐derived EVs for CD63, CD90 and PDPN under non‐fixed, non‐permeabilised conditions. Data are shown for two representative arthritis‐derived synovial fibroblast EV preparations (RA and OA). (d) Representative Western blot analysis of SEC‐UF‐enriched EVs and corresponding cell lysates (CL) from two arthritis‐derived synovial fibroblasts (RA and OA). Blots were probed for canonical EV markers (CD63, CD9, CD81, syntenin‐1, annexin‐1, flotillin‐1), fibroblast‐associated markers (CD90, PDPN) and the EV exclusion marker calnexin. (e) Representative Western blot analysis of cytosolic (C) and membrane‐enriched (M) protein fractions from cell and SEC‐UF‐enriched EV lysates of two arthritis‐derived synovial fibroblasts preparations (RA and OA). Blots were probed for CD90, PDPN and for canonical EV markers (CD63, CD9, syntenin‐1, annexin‐1, flotillin‐1). (f) Schematic of magnetic bead‐based immunocapture of SEC‐UF‐enriched EVs using nanosised beads coupled to anti‐CD90 or anti‐PDPN antibodies, or matched isotype control antibodies. Marker‐negative or non‐captured EVs were collected in the flowthrough (FT), followed by collection of a wash fraction (W). Bead‐bound marker‐positive EVs were recovered in the first eluate (E1), with a second eluate (E2) collected to assess residual carryover and elution efficiency. (g) Representative TEM images of E and FT fractions following CD90‐ or PDPN‐directed immunocapture; arrows indicate EVs. (h) Representative Western blot analysis of EV fractions obtained after CD90‐ and PDPN‐directed immunocapture, including the EV input control (EV CTRL), fractions E1‐E2, W, FT and corresponding isotype‐bead control. Blots were probed for CD90, PDPN and canonical EV markers (CD63, CD9, syntenin‐1, annexin‐1, flotillin‐1). (i) Densitometric quantification of immunocapture outcomes from Western blot analyses of n = 3 independent experiments using SEC‐UF‐enriched EVs from synovial fibroblasts of different arthritis patients, shown as log 2 relative density ratios for proteins of interest after normalisation to syntenin‐1. Paired E‐versus‐FT comparisons were assessed by paired Student's t ‐test (ns, not significant; * p < 0.05; ** p < 0.005; *** p < 0.001). Lines connect matched E‐FT pairs. P1 and P2 denote two PDPN signal populations resolved by immunoblot.

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: In Vitro validation of CD90‐ and PDPN‐directed immunocapture of synovial fibroblast‐derived EVs following SEC‐UF enrichment. (a) Schematic of the size exclusion chromatography‐ultrafiltration (SEC‐UF) workflow used to enrich EVs from conditioned medium (CM) of cultured synovial fibroblasts. (b) Representative transmission electron microscopy (TEM) images of SEC‐UF‐enriched EVs from two arthritis‐derived synovial fibroblasts (RA and OA donor). (c) Nano‐flow cytometry (nFCM) single‐vesicle surface staining of synovial fibroblast‐derived EVs for CD63, CD90 and PDPN under non‐fixed, non‐permeabilised conditions. Data are shown for two representative arthritis‐derived synovial fibroblast EV preparations (RA and OA). (d) Representative Western blot analysis of SEC‐UF‐enriched EVs and corresponding cell lysates (CL) from two arthritis‐derived synovial fibroblasts (RA and OA). Blots were probed for canonical EV markers (CD63, CD9, CD81, syntenin‐1, annexin‐1, flotillin‐1), fibroblast‐associated markers (CD90, PDPN) and the EV exclusion marker calnexin. (e) Representative Western blot analysis of cytosolic (C) and membrane‐enriched (M) protein fractions from cell and SEC‐UF‐enriched EV lysates of two arthritis‐derived synovial fibroblasts preparations (RA and OA). Blots were probed for CD90, PDPN and for canonical EV markers (CD63, CD9, syntenin‐1, annexin‐1, flotillin‐1). (f) Schematic of magnetic bead‐based immunocapture of SEC‐UF‐enriched EVs using nanosised beads coupled to anti‐CD90 or anti‐PDPN antibodies, or matched isotype control antibodies. Marker‐negative or non‐captured EVs were collected in the flowthrough (FT), followed by collection of a wash fraction (W). Bead‐bound marker‐positive EVs were recovered in the first eluate (E1), with a second eluate (E2) collected to assess residual carryover and elution efficiency. (g) Representative TEM images of E and FT fractions following CD90‐ or PDPN‐directed immunocapture; arrows indicate EVs. (h) Representative Western blot analysis of EV fractions obtained after CD90‐ and PDPN‐directed immunocapture, including the EV input control (EV CTRL), fractions E1‐E2, W, FT and corresponding isotype‐bead control. Blots were probed for CD90, PDPN and canonical EV markers (CD63, CD9, syntenin‐1, annexin‐1, flotillin‐1). (i) Densitometric quantification of immunocapture outcomes from Western blot analyses of n = 3 independent experiments using SEC‐UF‐enriched EVs from synovial fibroblasts of different arthritis patients, shown as log 2 relative density ratios for proteins of interest after normalisation to syntenin‐1. Paired E‐versus‐FT comparisons were assessed by paired Student's t ‐test (ns, not significant; * p < 0.05; ** p < 0.005; *** p < 0.001). Lines connect matched E‐FT pairs. P1 and P2 denote two PDPN signal populations resolved by immunoblot.

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: In Vitro, Biomarker Discovery, Derivative Assay, Size-exclusion Chromatography, Cell Culture, Transmission Assay, Electron Microscopy, Flow Cytometry, Staining, Western Blot, Analysis, Marker, Membrane, Control

    CD90‐directed immunocapture selectively retrieves CD90+ EVs from mixed EV preparations and synovial fluid‐spiked samples. (a) Schematic of immunocapture from a defined mixed EV preparation generated by combining SEC‐UF‐enriched EVs from synovial fibroblasts and THP‐1 macrophages at a 1:1 ratio. CD90 + EVs are captured and eluted (E1, E2), while unbound EVs are collected as flowthrough (FT) and wash (W). (b) Representative Western blot analysis of E and FT fractions from the CD90‐directed immunocapture using the mixed EV preparation, probed for CD90, PDPN, CD68 and for canonical EV markers CD63, CD9 and syntenin‐1. An isotype‐bead control was included to assess capture specificity. EV input controls (bulk SEC‐UF‐enriched EVs prior to immunocapture) from each source are shown. Densitometric quantification of CD90‐directed immunocapture outcomes from Western blot analyses of n = 3 independent experiments using SEC‐UF‐enriched EVs from synovial fibroblasts of different arthritis patients, shown as log 2 relative density ratios for CD90, PDPN and CD68 after normalisation to syntenin‐1. Paired E‐versus‐FT comparisons were assessed by paired Student's t ‐test (** p < 0.005; *** p < 0.001). Lines connect matched E‐FT pairs. (c) Schematic of CD90‐directed immunocapture following spiking of synovial fibroblast‐derived SEC‐UF‐enriched EVs into a pre‐treated synovial fluid sample lacking detectable endogenous CD90 signal. The fractions E1, E2, W and FT were collected; unbound EVs in FT were subsequently purified and enriched by SEC‐UF as indicated. (d) Representative Western blot analysis of E1 and E2, FT and W fractions from synovial‐fluid spiked‐in experiments, probed for CD90, PDPN and for canonical EV markers CD63, CD9 and syntenin‐1, with an isotype‐bead control and EV input control (spiked SEC‐UF EV population). Densitometric quantification of immunocapture outcomes shown as log 2 relative density ratios for CD90 signal intensity normalised to syntenin‐1. No statistical assessment was performed from the paired E1 versus FT, as no CD90 signal was detectable in the FT fraction (nd, not detected).

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: CD90‐directed immunocapture selectively retrieves CD90+ EVs from mixed EV preparations and synovial fluid‐spiked samples. (a) Schematic of immunocapture from a defined mixed EV preparation generated by combining SEC‐UF‐enriched EVs from synovial fibroblasts and THP‐1 macrophages at a 1:1 ratio. CD90 + EVs are captured and eluted (E1, E2), while unbound EVs are collected as flowthrough (FT) and wash (W). (b) Representative Western blot analysis of E and FT fractions from the CD90‐directed immunocapture using the mixed EV preparation, probed for CD90, PDPN, CD68 and for canonical EV markers CD63, CD9 and syntenin‐1. An isotype‐bead control was included to assess capture specificity. EV input controls (bulk SEC‐UF‐enriched EVs prior to immunocapture) from each source are shown. Densitometric quantification of CD90‐directed immunocapture outcomes from Western blot analyses of n = 3 independent experiments using SEC‐UF‐enriched EVs from synovial fibroblasts of different arthritis patients, shown as log 2 relative density ratios for CD90, PDPN and CD68 after normalisation to syntenin‐1. Paired E‐versus‐FT comparisons were assessed by paired Student's t ‐test (** p < 0.005; *** p < 0.001). Lines connect matched E‐FT pairs. (c) Schematic of CD90‐directed immunocapture following spiking of synovial fibroblast‐derived SEC‐UF‐enriched EVs into a pre‐treated synovial fluid sample lacking detectable endogenous CD90 signal. The fractions E1, E2, W and FT were collected; unbound EVs in FT were subsequently purified and enriched by SEC‐UF as indicated. (d) Representative Western blot analysis of E1 and E2, FT and W fractions from synovial‐fluid spiked‐in experiments, probed for CD90, PDPN and for canonical EV markers CD63, CD9 and syntenin‐1, with an isotype‐bead control and EV input control (spiked SEC‐UF EV population). Densitometric quantification of immunocapture outcomes shown as log 2 relative density ratios for CD90 signal intensity normalised to syntenin‐1. No statistical assessment was performed from the paired E1 versus FT, as no CD90 signal was detectable in the FT fraction (nd, not detected).

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: Generated, Western Blot, Analysis, Control, Derivative Assay, Purification

    SEC‐UF enrichment enables CD90‐ and PDPN‐directed immunocapture of stromal‐associated EV populations from arthritic synovial fluid. (a) Schematic of the synovial fluid pre‐treatment and SEC‐UF EV enrichment workflow, followed by magnetic bead‐based immunocapture using nanosised antibody‐coupled beads. (b) Representative transmission electron microscopy (TEM) images of two independent synovial fluid preparations with and without SEC‐UF processing, illustrating the reduction of visually apparent background material and recovery of EVs following the enrichment workflow. (c) Western blot analysis of SEC‐UF‐enriched SF‐EV preparations from three arthritis patients (Patients 5, 7 and 8), probed for stromal‐associated markers (CD90, PDPN), selected myeloid/immune‐associated markers (CD68, CD48, CD163) and syntenin‐1. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts and M1‐like macrophages were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, all marker panels shown were derived from the same immunoblot. (d) Western blot analysis and densitometric quantification of EV fractions obtained after immunocapture in SEC‐UF‐enriched SF‐EVs using anti‐CD90 or anti‐PDPN beads, shown for patients 5, 7 and 8. Eluate (E), flowthrough (FT) and wash (W) fractions are displayed on the same immunoblot; total recovered protein material from each fraction was analysed. Stromal‐associated signals (CD90, PDPN; red frames) and selected myeloid/immune‐associated signals (CD163, CD68, CD48; blue frames) are indicated, together with probed canonical EV markers (CD63, CD9, syntenin‐1) and human serum albumin. For quantification, band intensities were normalised to syntenin‐1 and expressed as log 2 relative density ratios. Paired E‐versus‐FT comparisons for CD90 and the two PDPN isoforms (P1 and P2) were assessed by paired Student's t ‐test (ns, not significant; * p < 0.05; ** p < 0.005; *** p < 0.001). Lines connect matched E–FT pairs. No statistical assessment was performed for the selected myeloid/immune‐associated markers because CD68, CD48 and CD163 signals were not detectable in the corresponding E fractions (nd, not detected).

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: SEC‐UF enrichment enables CD90‐ and PDPN‐directed immunocapture of stromal‐associated EV populations from arthritic synovial fluid. (a) Schematic of the synovial fluid pre‐treatment and SEC‐UF EV enrichment workflow, followed by magnetic bead‐based immunocapture using nanosised antibody‐coupled beads. (b) Representative transmission electron microscopy (TEM) images of two independent synovial fluid preparations with and without SEC‐UF processing, illustrating the reduction of visually apparent background material and recovery of EVs following the enrichment workflow. (c) Western blot analysis of SEC‐UF‐enriched SF‐EV preparations from three arthritis patients (Patients 5, 7 and 8), probed for stromal‐associated markers (CD90, PDPN), selected myeloid/immune‐associated markers (CD68, CD48, CD163) and syntenin‐1. Cell lysates (CL; 2.5 µg per lane) from cultured synovial fibroblasts and M1‐like macrophages were included as positive controls for antibody reactivity and to confirm cell‐type‐association. For each patient sample, all marker panels shown were derived from the same immunoblot. (d) Western blot analysis and densitometric quantification of EV fractions obtained after immunocapture in SEC‐UF‐enriched SF‐EVs using anti‐CD90 or anti‐PDPN beads, shown for patients 5, 7 and 8. Eluate (E), flowthrough (FT) and wash (W) fractions are displayed on the same immunoblot; total recovered protein material from each fraction was analysed. Stromal‐associated signals (CD90, PDPN; red frames) and selected myeloid/immune‐associated signals (CD163, CD68, CD48; blue frames) are indicated, together with probed canonical EV markers (CD63, CD9, syntenin‐1) and human serum albumin. For quantification, band intensities were normalised to syntenin‐1 and expressed as log 2 relative density ratios. Paired E‐versus‐FT comparisons for CD90 and the two PDPN isoforms (P1 and P2) were assessed by paired Student's t ‐test (ns, not significant; * p < 0.05; ** p < 0.005; *** p < 0.001). Lines connect matched E–FT pairs. No statistical assessment was performed for the selected myeloid/immune‐associated markers because CD68, CD48 and CD163 signals were not detectable in the corresponding E fractions (nd, not detected).

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: Transmission Assay, Electron Microscopy, Western Blot, Analysis, Cell Culture, Marker, Derivative Assay

    Surfaceome‐informed cell‐of‐origin profiling links eluate‐ and flowthrough‐enriched SF‐EV proteins to stromal‐ versus immune‐associated cell signatures. (a) Volcano plot of differential protein abundance between the CD90‐immunocaptured synovial fluid (SF) EV eluate fraction (E) and the non‐captured CD90 − flowthrough fraction (FT). Protein's meeting significance and effect‐size thresholds (FDR < 0.05; |log 2 FC| ≥ 1.5) are highlighted (red dots); selected membrane‐associated proteins are annotated as indicated. (b) Box plots showing log 2 ‐normalised abundance values for representative proteins enriched in the E fraction (upper panel) or FT fraction (lower panel), as indicated. Box plots show median and interquartile range (IQR); whiskers indicate the 5th–95th percentiles. (c) Distribution of significantly enriched surface proteins across curated cell‐type signature (CTS) groups. Proteins were restricted to those with cell surface protein consensus (SPC) scores 4–3–2 and assigned to 10 CTS groups; counts are shown for E‐ versus FT‐enriched proteins, as indicated. (d) Venn diagrams comparing E‐ and FT‐enriched protein sets (SPC score 4–3–2) with published synovial fibroblast and synovial tissue single‐cell transcriptomic reference datasets (Korsunsky et al. ; Edalat et al. ), as cited in the main text). (e, f) Projection of E‐ and FT‐enriched proteins onto two independent single‐cell gene expression atlases: (e) Broad Institute Single Cell Portal (SCP; AMP Phase I RA synovial tissue dataset; Zhang et al., ) and (f) Tabula Sapiens. Dot plots/UMAP representations show the distribution of mapped proteins (as shown in Panel d) across annotated cell types as displayed in each atlas. In Panel e, dot size denotes the proportion of cells within a given cell type annotation expressing the corresponding gene, and dot colour density indicates the average expression level, as displayed. In Panel f, coloured circles in UMAP plots depict annotated cell type clusters. (g) Schematic summary of membrane proteins enriched in the CD90‐immunocaptured SF‐EV subpopulation (Eluate fraction) versus membrane proteins enriched in the heterogenous pool of non‐captured CD90 − SF‐EV populations (flowthrough fraction). Figure created with BioRender.com.

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: Surfaceome‐informed cell‐of‐origin profiling links eluate‐ and flowthrough‐enriched SF‐EV proteins to stromal‐ versus immune‐associated cell signatures. (a) Volcano plot of differential protein abundance between the CD90‐immunocaptured synovial fluid (SF) EV eluate fraction (E) and the non‐captured CD90 − flowthrough fraction (FT). Protein's meeting significance and effect‐size thresholds (FDR < 0.05; |log 2 FC| ≥ 1.5) are highlighted (red dots); selected membrane‐associated proteins are annotated as indicated. (b) Box plots showing log 2 ‐normalised abundance values for representative proteins enriched in the E fraction (upper panel) or FT fraction (lower panel), as indicated. Box plots show median and interquartile range (IQR); whiskers indicate the 5th–95th percentiles. (c) Distribution of significantly enriched surface proteins across curated cell‐type signature (CTS) groups. Proteins were restricted to those with cell surface protein consensus (SPC) scores 4–3–2 and assigned to 10 CTS groups; counts are shown for E‐ versus FT‐enriched proteins, as indicated. (d) Venn diagrams comparing E‐ and FT‐enriched protein sets (SPC score 4–3–2) with published synovial fibroblast and synovial tissue single‐cell transcriptomic reference datasets (Korsunsky et al. ; Edalat et al. ), as cited in the main text). (e, f) Projection of E‐ and FT‐enriched proteins onto two independent single‐cell gene expression atlases: (e) Broad Institute Single Cell Portal (SCP; AMP Phase I RA synovial tissue dataset; Zhang et al., ) and (f) Tabula Sapiens. Dot plots/UMAP representations show the distribution of mapped proteins (as shown in Panel d) across annotated cell types as displayed in each atlas. In Panel e, dot size denotes the proportion of cells within a given cell type annotation expressing the corresponding gene, and dot colour density indicates the average expression level, as displayed. In Panel f, coloured circles in UMAP plots depict annotated cell type clusters. (g) Schematic summary of membrane proteins enriched in the CD90‐immunocaptured SF‐EV subpopulation (Eluate fraction) versus membrane proteins enriched in the heterogenous pool of non‐captured CD90 − SF‐EV populations (flowthrough fraction). Figure created with BioRender.com.

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: Profiling, Quantitative Proteomics, Membrane, Tissue, Single Cell, Gene Expression, Expressing

    Selected CD markers ( n = 150) detected in synovial fluid EVs from arthritis patients and grouped by cell‐type association.

    Journal: Journal of Extracellular Vesicles

    Article Title: Enrichment and Proteomic Profiling of Stromal‐Associated Extracellular Vesicle Subpopulations From Arthritic Synovial Fluid by Size‐Exclusion Chromatography Coupled to CD90‐Directed Immunocapture

    doi: 10.1002/jev2.70353

    Figure Lengend Snippet: Selected CD markers ( n = 150) detected in synovial fluid EVs from arthritis patients and grouped by cell‐type association.

    Article Snippet: The membrane was blocked in blocking buffer (5% milk in TBS with 0.05% Tween20 [TBS‐T]) for 1 h at RT, followed by three washing steps for 5 min in washing buffer (TBS‐T) and an overnight incubation with primary antibodies at 4°C (CD90 (CST‐13801S‐Rabbit; 1:1000), PDPN (CST‐9047‐Rabbit; 1:1000), CD68 (UltraMAB‐UM870047‐Mouse; 1:2000), CD63 (Invitrogen‐10628D‐Mouse; 1:1000), CD9 (Invitrogen‐10626D‐Mouse; 1:1000), CD81 (Invitrogen‐10630D‐Mouse; 1:1000), CD163 (CST‐93498‐Rabbit; 1:1000), Syntenin‐1 (Abcam‐ab133267‐Rabbit; 1:1000), Flotillin‐1 (BD‐610820‐Mouse; 1:1000), Annexin‐1 (BD‐610067‐Mouse; 1:5000), Calnexin (CST‐2679S‐Rabbit; 1:1000), CD48 (CST‐29499T‐Rabbit; 1:1000)).

    Techniques: